Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Praised in Technical420 Article
- Lexaria Bioscience Corp. featured in a Technical420 article praising the company’s recent developments
- Lexaria is improving and strengthening patent portfolio; 19 patent applications are pending in more than 40 countries
- Company executes partnership with NeutriSci International; joint venture allows LXRP to enter Asian market
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), an innovative company licensing proprietary technology for the delivery of bioactive compounds including cannabinoids, is a “plant-to-bloodstream” company expected to draw investors in the cannabis marketplace. Lexaria has patented and licenses a novel delivery system that infuses organically sourced hemp oil into the molecules of other substances.
Cannabidiol, noted for its anti-inflammatory, anxiolytic, antiemetic and antipsychotic effects, is just one of several compounds targeted by Lexaria for its unique oral ingestion technology, which allows more efficient delivery of bioactive substances via oral ingestion without the need for unhealthy inhalation or the addition of sweeteners commonly used to mask bitter tastes. Non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and vitamins are among the substances targeted by Lexaria’s new delivery method.
A recent article in Technical420 (http://nnw.fm/0IT6s), a provider of research and analysis of cannabis stocks, praised the company for several positive developments over the past few months.
Lexaria has 19 patent applications filed and pending in more than 40 countries worldwide. The company strengthened its intellectual property portfolio with its first U.S. patent, issued in October 2016. The patent protects Lexaria’s intellectual property for infusion of cannabinoid compounds in edible products. Lexaria’s unique process improves the taste and bioavailability of cannabinoid food ingredients.
Another strong development is Lexaria’s joint venture with NeutriSci International (TSX.V: NU), a Canadian public company, to produce and sell a line of healthy edible cannabinoid products. The two companies will produce a line of cannabinoid mouth-melt products using Lexaria’s technology and NeutriSci’s proprietary pterostilbene tablet. Pterostilbene is an antioxidant that’s chemically similar to Resveratrol – a natural compound found primarily in blueberries and Pterocarpus marsupium heartwood, according to the U.S. National Library of Medicine (http://nnw.fm/Euz95).
The joint venture will operate as Ambarii Trade Corporations, and initial operations will be funded equally by Lexaria and NeutriSci. AMbarii’s plans include securing licensees in Canada, California and Colorado to produce mouth-melt products containing THC.
Lexaria is also venturing into the Asian market, as noted by the Technical420 article. Ambarii has entered into an LOI with Naturally Splendid Enterprises Ltd. (TSX.V: NSP) for production and distribution of the company’s sublingual full spectrum cannabidiol tablets in Japan and South Korea. With a population of 127 million, Japan is one of the world’s largest markets, and hemp oil containing cannabidiol is already legal in Japan. South Korea, with a population of 50 million, is expected to open its markets to hemp oil-sourced cannabidiol soon.
Lexaria will begin in vitro absorption studies to quantify improvements in absorption in human intestinal tissue and will conduct animal studies on whole-body reactions to the rapid and efficient delivery of cannabinoids, vitamins, NSAIDs and nicotine. Edible nicotine products could allow a healthier alternative to smoking, patches and nicotine gum. The article points out that the company’s R&D budget is fully funded from existing capital.
Lexaria has an improved cash position and an attractive valuation, the Technical420 article states, due to improved balance sheets and a much smaller warrant overhang. The company raised more than $1.7 million in April, and, from November 2016 through May 2017, the company raised more than $4 million in equity. Technical420 is “favorable” on these developments and expects to see significant advancement by Lexaria Bioscience.
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria Bioscience Corp. featured in a Technical420 article praising the company’s recent developments
- Lexaria is improving and strengthening patent portfolio; 19 patent applications are pending in more than 40 countries
- Company executes partnership with NeutriSci International; joint venture allows LXRP to enter Asian market
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), an innovative company licensing proprietary technology for the delivery of bioactive compounds including cannabinoids, is a “plant-to-bloodstream” company expected to draw investors in the cannabis marketplace. Lexaria has patented and licenses a novel delivery system that infuses organically sourced hemp oil into the molecules of other substances.
Cannabidiol, noted for its anti-inflammatory, anxiolytic, antiemetic and antipsychotic effects, is just one of several compounds targeted by Lexaria for its unique oral ingestion technology, which allows more efficient delivery of bioactive substances via oral ingestion without the need for unhealthy inhalation or the addition of sweeteners commonly used to mask bitter tastes. Non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and vitamins are among the substances targeted by Lexaria’s new delivery method.
A recent article in Technical420 (http://nnw.fm/0IT6s), a provider of research and analysis of cannabis stocks, praised the company for several positive developments over the past few months.
Lexaria has 19 patent applications filed and pending in more than 40 countries worldwide. The company strengthened its intellectual property portfolio with its first U.S. patent, issued in October 2016. The patent protects Lexaria’s intellectual property for infusion of cannabinoid compounds in edible products. Lexaria’s unique process improves the taste and bioavailability of cannabinoid food ingredients.
Another strong development is Lexaria’s joint venture with NeutriSci International (TSX.V: NU), a Canadian public company, to produce and sell a line of healthy edible cannabinoid products. The two companies will produce a line of cannabinoid mouth-melt products using Lexaria’s technology and NeutriSci’s proprietary pterostilbene tablet. Pterostilbene is an antioxidant that’s chemically similar to Resveratrol – a natural compound found primarily in blueberries and Pterocarpus marsupium heartwood, according to the U.S. National Library of Medicine (http://nnw.fm/Euz95).
The joint venture will operate as Ambarii Trade Corporations, and initial operations will be funded equally by Lexaria and NeutriSci. AMbarii’s plans include securing licensees in Canada, California and Colorado to produce mouth-melt products containing THC.
Lexaria is also venturing into the Asian market, as noted by the Technical420 article. Ambarii has entered into an LOI with Naturally Splendid Enterprises Ltd. (TSX.V: NSP) for production and distribution of the company’s sublingual full spectrum cannabidiol tablets in Japan and South Korea. With a population of 127 million, Japan is one of the world’s largest markets, and hemp oil containing cannabidiol is already legal in Japan. South Korea, with a population of 50 million, is expected to open its markets to hemp oil-sourced cannabidiol soon.
Lexaria will begin in vitro absorption studies to quantify improvements in absorption in human intestinal tissue and will conduct animal studies on whole-body reactions to the rapid and efficient delivery of cannabinoids, vitamins, NSAIDs and nicotine. Edible nicotine products could allow a healthier alternative to smoking, patches and nicotine gum. The article points out that the company’s R&D budget is fully funded from existing capital.
Lexaria has an improved cash position and an attractive valuation, the Technical420 article states, due to improved balance sheets and a much smaller warrant overhang. The company raised more than $1.7 million in April, and, from November 2016 through May 2017, the company raised more than $4 million in equity. Technical420 is “favorable” on these developments and expects to see significant advancement by Lexaria Bioscience.
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
